Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to examine the mechanisms of transcutaneous spinal cord stimulation (tSCS) for improving cardiovascular and pulmonary function in individuals with chronic motor-complete spinal cord injury (SCI) by measuring vascular related endothelial biomarkers, plasma catecholamines, and respiratory parameters.


Clinical Trial Description

DETAILED RESEARCH PROCEDURES (A) INFORMED CONSENT: Prospective participants will be provided with the study informed consent form and will be given at least 24 hours to review the form, ask questions, and discuss with whomever they like. (B) VISIT 1 -Screening Approximately 1 hour Individuals who agree to participate in the study will be invited for a screening assessment to confirm study eligibility. After the individual has provided informed consent, they will be assigned a unique study identification number and the information listed below will be collected. Screening questionnaires and assessments: - Inclusion/Exclusion Criteria confirmation - Demographics - Medical history and history of injury - Concomitant medication use - Weight and height - Previous allergies and adverse events to medications - Pregnancy screening will be performed - Internationals Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam (C) VISITS 2-5 -Baseline functional assessments, questionnaires, and cardiopulmonary assessments Approximately 2 hours per visit Enrolled participants will complete questionnaires after which a spirometry assessment for pulmonary function will be performed. Participants will be provided with a 24-hour Ambulatory Blood Pressure Monitor (24- ABPM) device to take home to record daily changes in cardiovascular parameters. Questionnaires (Visit 2): - Short-form (36) Health Survey (SF-36) - Autonomic Dysfunction following SCI (ADFSCI) questionnaire - Leisure Time Physical Activity Questionnaire after SCI (LTPAQ-SCI). - National Health Interview Survey - Chronic Conditions - American Thoracic Society (ATS) Adult Respiratory Disease Survey. - Tobacco Use Baseline cardiopulmonary and optional functional assessments (with and without tSCS) (Visits 2-5): - Spirometry testing (Visit 2) - 24-hour Ambulatory Blood Pressure and electrocardiogram Monitoring (24-hr ABP and ECG Monitor) (Visit 2) - Somatosensory evoked potentials (Visit 3, optional) - Transcranial Magnetic Stimulation (Visit 4, optional) - H-reflex (Visit 5, optional) - Compound Muscle Action Potentials (Peripheral nerve stimulation) (Visit 5, optional) - Muscle Ultrasound (Visit 5, optional) Participants will also be provided with instructions to prepare for Visit 3 or 6 (depending on whether they do the optional assessments), during which blood samples will be collected. Participants will be asked to: - Arrive for testing in a fasted state (fasted for 12 hours, but they may continue to drink water) - Not consume caffeine, recreational drugs, alcohol, smoking, or antihypotensive drug (e.g., midodrine) for 12 hours prior to their appointment - No strenuous exercise within 24 hours of the start of the study. (D) VISITS 3-5 or 6-8 (depending on whether or not the optional functional assessments were completed earlier in the study). Baseline cardiovascular assessments and blood draws. Approximately 3 hours In this session, participants will return the 24-hour ABP and ECG Monitor and undergo baseline cardiovascular assessments as well as the blood draws. The participant has the option of only taking part in one or all cardiovascular assessments. If the participant chooses to undergo more than one cardiovascular assessment they will be conducted on different visits. Cardiovascular Assessments: • Cardiovascular stress test (orthostatic stress test and/or vibrostimulation or DARS) Blood Draws: Four (4) blood draws will be taken: 1. At rest without tSCS 2. At rest with tSCS 3. During cardiovascular stress test without tSCS 4. During cardiovascular stress test with tSCS (E) TREATMENT VISITS (minimum 12 tSCS visits, depending on whether or not the optional functional and cardiovascular assessments were done earlier in the study) to completion of long-term intervention with tSCS intervention: Each session will last approximately 90 minutes (set-up AND at least 45min of tSCS treatment). Long-term tSCS is scheduled to last for a minimum of two times per week for 6 weeks. Following the completion of the intervention, participants will begin post-intervention questionnaires and cardiopulmonary assessments. Week to week variation in the number of scheduled sessions may vary due to varying circumstances (e.g., scheduling, transportation, participant health). However, the total number of sessions conducted will be the same as the participant's original goal. (F) SECOND TO LAST VISIT: Post-intervention questionnaires and cardiopulmonary assessment: Approximately 2 hours In this session, participants will complete post-intervention questionnaires and undergo post-intervention cardiopulmonary assessments. Questionnaires: - Short-form (36) Health Survey (SF-36) - Autonomic Dysfunction following SCI (ADFSCI) questionnaire - Leisure Time Physical Activity Questionnaire after SCI (LTPAQ-SCI). - National Health Interview Survey - Chronic Conditions - American Thoracic Society (ATS) Adult Respiratory Disease Survey. - Tobacco Use Cardiopulmonary Assessments: - Spirometry testing - 24-hour ABP and ECG Monitor (G) LAST VISIT: Post-intervention cardiovascular assessments and blood draws: Approximately 3 hours In this session, participants will undergo post-intervention cardiovascular assessments as well as the blood draws. Cardiovascular Assessments: - Carotid and cardiac ultrasound - Cardiovascular stress test (orthostatic hypotension stress and/or vibrostimulation or DARS) Blood Draws: Four (4) blood draws will be taken: 1. At rest without tSCS 2. At rest with tSCS 3. During a cardiovascular stress without tSCS 4. During a cardiovascular stress with tSCS ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06379711
Study type Interventional
Source University of British Columbia
Contact Andrea Maharaj, BSc
Phone 6046758856
Email amaharaj@icord.org
Status Not yet recruiting
Phase N/A
Start date August 1, 2024
Completion date August 1, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)